Atuzabrutinib Topical Gel Does Not Improve Disease Activity in Patients with Mild-to-Moderate Atopic Dermatitis: Findings from a Phase 2A Trial
J Invest Dermatol
.
2025 May 5:S0022-202X(25)00462-2.
doi: 10.1016/j.jid.2025.03.046.
Online ahead of print.
Authors
Mark Lee
1
,
Vincent Mikol
2
,
Vinh Truong
3
,
Elham Attieh
2
,
Siying Huang
3
,
Marie Vigan
3
,
Maria Wiekowski
4
,
Christine Xu
4
,
Ben Lin
5
,
Dany Nassar
6
Affiliations
1
Progressive Clinical Research, San Antonio, Texas, USA.
2
Sanofi, Vitry-Sur-Seine, France.
3
Ividata Life Sciences, Levallois-Perret, France.
4
Sanofi, Bridgewater, New Jersey, USA.
5
Sanofi, Cambridge, Massachusetts, USA. Electronic address: ben.lin@sanofi.com.
6
Sanofi, Gentilly, France.
PMID:
40335015
DOI:
10.1016/j.jid.2025.03.046
No abstract available
Keywords:
Atopic dermatitis; Bruton’s tyrosine kinase inhibitor; Eczema; Pruritus; Skin lesions.